MedTrace Logo

Atorvastatin Plus Escitalopram for Depression With Dyslipidemia

NCT07712367 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-07-21

No results posted yet for this study

Summary

This is a clinical observation study. We want to learn more about two common prescription medicines used together for adults. These medicines treat low mood and high blood fat.

The two medicines are escitalopram for mood symptoms and atorvastatin for high blood fat. Both medicines are approved and routinely used in hospitals.

This study answers two simple questions:

* Does taking these two medicines together improve patients' mood?
* Does this medicine combination improve blood fat levels and have safe results? Study participants are adult patients who have symptoms of depression and high blood fat. This study uses no experimental drugs or new medical devices. All treatment follows standard hospital care.

During the study, participants take their regular medicines as prescribed by their doctors. The study team collects routine health information during normal clinic visits. We check mood scores and blood fat test results. We also record any mild side effects, such as dizziness or stomach upset.

This study adds no extra tests, no extra procedures, and no extra costs for participants. Joining this study is voluntary. Participants may stop at any time. Stopping the study will not change their regular medical care. All personal health data stays private and protected.

Conditions

  • Depressive Episode, Dyslipidemia

Interventions

DRUG

Escitalopram plus atorvastatin

Patients with depressive episode and dyslipidemia receive standard oral escitalopram combined with atorvastatin as routine clinical treatment.

Sponsors & Collaborators

  • Hengshui City Seventh People's Hospital

    lead OTHER

Principal Investigators

  • bei bei zhang, Bachelor's degree · Hengshui City Seventh People's Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2026-05-10
Completion
2026-05-27
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07712367 on ClinicalTrials.gov